Blockchain Registration Transaction Record
VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
VERAXA Biotech (VRXA) completes business combination with Voyager Acquisition Corp., begins trading on Nasdaq. Learn about its BiTAC platform for cancer therapy.
This news matters because VERAXA Biotech's novel BiTAC platform has the potential to revolutionize cancer treatment by offering more targeted therapies with fewer side effects. The successful business combination and Nasdaq listing provide the company with the capital and visibility needed to advance its pipeline toward clinical trials, bringing hope to patients with difficult-to-treat cancers. Investors and the biotech community should watch for upcoming clinical data that could validate this innovative approach.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0x959202ac6305e6b0c6b104fa1d8983d03274a2a0a0c02bba67094124f860ee85 |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | wolfq2gI-3494f59d1889e0e280ada2bf55fed119 |